Creative Biolabs engineers B. subtilis for secretion and spore traits via genome editing, signal peptide screening, and pathway rewiring. We support plasmid and chromosomal integration, build strain libraries, and verify genetic stability under process-relevant stresses, delivering candidate strains tailored for functional research, chassis applications, or spore-based delivery concepts with traceable design records and release criteria.
We quantify how B. subtilis performs under heat, desiccation, shear, oxidative stress, gastric acid, and bile salts. Using spore fraction, CFU retention, and recovery kinetics, we define tolerance thresholds and critical process windows that guide fermentation, drying, and formulation decisions, enabling rational selection of protectants and process parameters for robust shelf and GI transit performance.
Our team develops aerobic or microaerobic B. subtilis fermentations across batch, fed-batch, and continuous modes from shake flask to pilot. We monitor spore ratio, secreted protein or metabolite titers, and run-to-run consistency. Process models and DoE shorten optimization cycles and de-risk transfer to larger bioreactors and continuous operations. Industrial-scale case studies inform scale-up targets.
For B. subtilis spores and soluble products (e.g., enzymes, lantibiotics), Creative Biolabs designs end-to-end clarification, concentration, purification, drying, and sterilization trains. We lock key process parameters (KPPs), yield windows, impurity profiles, and particle attributes, providing scalable unit-operation recipes compatible with GMP-like environments and future validation paths. Bacteriocin handling options are available when applicable.
We formulate B. subtilis as powders, granules, capsules, or liquids. Using carrier matrices and protectant systems, we improve shelf stability and GI passage performance. Formulations are stress-challenged (temperature, humidity, light, freeze-thaw) and modeled for expiry prediction. Output includes target CFU/spore recovery specifications and packaging recommendations aligned to your use scenario and logistics profile.
Creative Biolabs conducts standardized antimicrobial susceptibility testing for B. subtilis, covering MIC/MBC determination, time-kill kinetics, and growth recovery under clinically relevant agents. Panels span antibiotics and bacteriocins; optional stress preconditioning reflects process realities. Outputs include susceptibility profiles, resistance trends, and method/SOP details to support risk assessment, strain selection, and comparative benchmarking in programs globally.
We characterize B. subtilis enzyme portfolios, biosurfactants, and antimicrobial peptides (e.g., bacteriocins such as subtilin/subtilosin), along with quorum-sensing and biofilm behaviors. Assays translate into mechanism-aligned data stories for publications or partner diligence. Optional comparative testing against reference strains clarifies differentiation and informs selection funnels for your program.
We perform B. subtilis safety-relevant screens: hemolysis, toxin/virulence gene checks, antibiotic susceptibility, and mobile element risk. We align with QPS-style thinking and document the absence of red-flag attributes to streamline stakeholder review and future regulatory dialogues outside this research service. Reports include methods, cutoffs, and interpretive notes.
Fig.1 MICs (mg/L) of 13 Antiobiotics for Bacillus subtilis
